These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37258648)

  • 21. The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation?
    Orlando VI
    Am J Law Med; 1999; 25(4):543-68. PubMed ID: 10629734
    [No Abstract]   [Full Text] [Related]  

  • 22. Patient-reported outcomes supporting anticancer product approvals.
    Rock EP; Kennedy DL; Furness MH; Pierce WF; Pazdur R; Burke LB
    J Clin Oncol; 2007 Nov; 25(32):5094-9. PubMed ID: 17991927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The FDA Struggle to Withdraw Makena: Problems With the Accelerated Approval Process.
    Aaron DG; Cohen IG; Adashi EY
    JAMA; 2022 Dec; 328(24):2394-2395. PubMed ID: 36480209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reforming Reimbursement for the US Food and Drug Administration's Accelerated Approval Program to Support State Medicaid Programs.
    Sachs RE; Donohue JM; Dusetzina SB
    JAMA Health Forum; 2022 Nov; 3(11):e224115. PubMed ID: 36399351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDA's New Guidance for Industry Addressing Evaluation of the Safety of New Drugs for Improving Glycemic Control: A Case Study in Regulatory Science.
    Rick Turner J
    Ther Innov Regul Sci; 2021 Jan; 55(1):1-5. PubMed ID: 33085070
    [No Abstract]   [Full Text] [Related]  

  • 26. FDA's post-approval studies continue to suffer delays and setbacks.
    Willyard C
    Nat Med; 2014 Nov; 20(11):1224-5. PubMed ID: 25375913
    [No Abstract]   [Full Text] [Related]  

  • 27. FDA's commitment to transparency.
    Guharoy R; Krenzelok E
    Am J Health Syst Pharm; 2021 Aug; 78(17):1550-1551. PubMed ID: 33599682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The ODAC Chronicles: Part 3. The FDA's philosophy and process for cancer drug evaluation and approval.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):1-5. PubMed ID: 15757431
    [No Abstract]   [Full Text] [Related]  

  • 29. Managing the Risks of Medicines: An Examination of FDA's Application of Criteria for Requiring a REMS.
    Seligman PJ; Anguiano RH; Felix T; Stabi K
    Ther Innov Regul Sci; 2019 Jul; 53(4):542-548. PubMed ID: 30226799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reflections on 10 years of the FDA's breakthrough therapy designation.
    Mullard A
    Nat Rev Drug Discov; 2022 Apr; 21(4):252-253. PubMed ID: 35292760
    [No Abstract]   [Full Text] [Related]  

  • 31. What Commissioner Gottlieb's FDA Is Doing to Lower Prescription Drug Prices and Steps Congress Can Take to Help.
    Waxman H; Corr B; Martin K; Duong S
    Issue Brief (Commonw Fund); 2018 Apr; 2018():1-10. PubMed ID: 29992802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The FDA's defensive status and how it affects patient care.
    Yarows SA
    Arch Intern Med; 2011 Jul; 171(13):1217. PubMed ID: 21747025
    [No Abstract]   [Full Text] [Related]  

  • 33. Surrogate endpoints and FDA's accelerated approval process.
    Fleming TR
    Health Aff (Millwood); 2005; 24(1):67-78. PubMed ID: 15647217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sowing confusion in the field: the interchangeable use of biosimilar terminology.
    McKinley L; Kelton JM; Popovian R
    Curr Med Res Opin; 2019 Apr; 35(4):619-621. PubMed ID: 30556742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inappropriate obstructions to access: the FDA's handling of plan B.
    Wood SF
    Virtual Mentor; 2014 Apr; 16(4):295-301. PubMed ID: 24735580
    [No Abstract]   [Full Text] [Related]  

  • 36. Characteristics of rare disease marketing applications associated with FDA product approvals 2006-2010.
    Pariser AR; Slack DJ; Bauer LJ; Warner CA; Tracy LA
    Drug Discov Today; 2012 Aug; 17(15-16):898-904. PubMed ID: 22564486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preserve the FDA's authority.
    Guharoy R
    Am J Health Syst Pharm; 1996 Nov; 53(21):2636, 2638. PubMed ID: 8913395
    [No Abstract]   [Full Text] [Related]  

  • 39. One hundred years of drug regulation: where do we go from here?
    Woosley RL
    Annu Rev Pharmacol Toxicol; 2013; 53():255-73. PubMed ID: 23072378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Flexibility and innovation in the FDA's novel regulatory approval strategies for hematologic drugs.
    Farrell AT; Goldberg KB; Pazdur R
    Blood; 2017 Sep; 130(11):1285-1289. PubMed ID: 28774876
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.